Related Experiment Video
Updated: May 3, 2026
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia
Francesco Mannelli1, Ilaria Cutini, Giacomo Gianfaldoni
1UF di Ematologia, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, and Istituto Toscano Tumori, Florence, Italy.
Background:
In acute myeloid leukemia (AML), CXCR4 expression has been correlated with leukocytosis and prognosis.
Methods:
We quantified CXCR4 expression by flow cytometry on leukemic cells in 142 AML patients.
Results:
We confirm a correlation between high CXCR4 expression and leukemic burden. Furthermore, we documented a correlation with platelet count, dysplastic megakaryopoiesis, hepato-splenomegaly and extra-hematological disease. NPM1-mutated AML displayed a significantly higher intensity of CXCR4 compared to NPM1-wt cases: it is conceivable its clinical phenotype to be driven by high CXCR4 expression.
Conclusions:
CXCR4 expression resulted in an independent prognostic factor. Our data support CXCR4 targeting as a potential therapeutic strategy.
More Related Videos
10:10HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
Published on: March 31, 2019
08:22Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production
Published on: May 31, 2020